Pancreatic Cancer Research

ResearcherNew York UniversityActive in the last 2 years

Jonathan Garnier

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5481-2926; OpenAlex author ID A5076298509. Sources: OpenAlex.

Their work

Papers
28 (first author 6, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
113
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 4 papers · 2021: 3 papers · 2022: 1 paper · 2023: 2 papers · 2024: 3 papers · 2025: 3 papers · 2026: 9 papers

Papers 28

  1. Survival benefit of recurrence-focused treatment after surgery for pancreatic ductal adenocarcinoma: A propensity score matched analysis of patients from a Dut… Co-author DOI 10.1016/j.ejca.2026.117776↗
  2. Stage-resolved gene drivers of pancreatic ductal adenocarcinoma progression and therapeutic vulnerabilities. Co-author DOI 10.1016/j.isci.2026.115164↗
  3. Postpancreatectomy liver injury: A relevant entity in the modern era of pancreatic cancer surgery with hepatic vessel resection. A monocentric retrospective co… Co-author DOI 10.1016/j.surg.2026.110302↗
  4. Pathway-driven therapeutic stratification in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2026.102920↗
  5. Proposal for an Objective and Concrete Definition for Determining Anatomic Resectability in Pancreatic Cancer: The Concept of the "Suitable Target". First author DOI 10.1097/xcs.0000000000001738↗
  6. Surgery for Locally Advanced Pancreatic Cancer: Oncological Landmarks for Venous and Arterial Reconstruction. Last author DOI 10.1245/s10434-025-18768-7↗
  7. ASO Visual Abstract: Surgery for Locally Advanced Pancreatic Cancer: Oncological Landmarks for Venous and Arterial Reconstruction. Last author DOI 10.1245/s10434-025-19023-9↗
  8. ASO Author Reflections: Arterial Reconstruction in Pancreatic Cancer: Shifting from Anatomical Feasibility Towards Biological Selection. Last author DOI 10.1245/s10434-026-19469-5↗
  9. Transcriptomic FOLFIRINOX sensitivity signatures stratify overall survival and reveal directional reclassification after neoadjuvant FOLFIRINOX in borderline r… Co-author DOI 10.64898/2026.09.07.749857↗
  10. Carbohydrate Antigen 19-9 Delta Function for Survival Prediction in Borderline Pancreatic Cancer. A PANC-PALS Consortium International Multicenter Derivation a… Co-author DOI 10.1097/sla.0000000000006735↗
  11. Two-Stage Mayo Clinic Class IIIb Celiac Axis Resection for Pancreatic Adenocarcinoma: Stepwise Management. Co-author DOI 10.1245/s10434-024-16673-z↗
  12. Prognosis Associated with Complete Pathological Response Following Neoadjuvant Treatment for PancreaTic AdenOcarciNOma in the FOFLIRINOX Era: the Multicenter T… Co-author DOI 10.1245/s10434-024-16735-2↗
  13. Influence of pancreatic fistula on survival after upfront pancreatoduodenectomy for pancreatic ductal adenocarcinoma: multicentre retrospective study. Co-author DOI 10.1093/bjsopen/zrae125↗
  14. Impact on survival of sarcopenia, systemic inflammatory response and anthropometric factors after pancreatectomy for resectable pancreatic adenocarcinoma. First author DOI 10.1186/s12957-024-03510-6↗
  15. Development of a Composite Score Based on Carbohydrate Antigen 19-9 Dynamics to Predict Survival in Carbohydrate Antigen 19-9-Producing Patients With Pancreati… Co-author DOI 10.1200/po.24.00193↗
  16. ASO Author Reflections: How to Tackle the Vascular Risk of Celiac Axis Resection for Pancreatic Cancer? Co-author DOI 10.1245/s10434-023-13422-6↗
  17. Management and outcomes of brain metastases from pancreatic adenocarcinoma: a pooled analysis and literature review. Co-author DOI 10.3389/fonc.2023.1326676↗
  18. Local Ablative Therapy Associated with Immunotherapy in Locally Advanced Pancreatic Cancer: A Solution to Overcome the Double Trouble?-A Comprehensive Review. Co-author DOI 10.3390/jcm11071948↗
  19. Does pre-operative embolization of a replaced right hepatic artery before pancreaticoduodenectomy for pancreatic adenocarcinoma affect postoperative morbidity … Co-author DOI 10.1016/j.hpb.2021.04.003↗
  20. Laser Treatment of Pancreatic Cancer with Immunostimulating Interstitial Laser Thermotherapy Protocol: Safety and Feasibility Results From Two Phase 2a Studies. Co-author DOI 10.1016/j.jss.2020.10.027↗
  21. Prospective Evaluation of Resection Margins Using Standardized Specimen Protocol Analysis among Patients with Distal Cholangiocarcinoma and Pancreatic Ductal A… Co-author DOI 10.3390/jcm10153247↗
  22. Borderline or locally advanced pancreatic adenocarcinoma: A single center experience on the FOLFIRINOX induction regimen. Co-author DOI 10.1016/j.ejso.2020.02.037↗
  23. Patient outcome according to the 2017 international consensus on the definition of borderline resectable pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.pan.2019.12.001↗
  24. Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study. Co-author DOI 10.1186/s12885-020-6690-1↗
  25. Has the non-resection rate decreased during the last two decades among patients undergoing surgical exploration for pancreatic adenocarcinoma? First author DOI 10.1186/s12893-020-00835-3↗
  26. Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma. First author DOI 10.1186/s12957-019-1637-1↗
  27. Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts. Co-author DOI 10.1016/j.celrep.2017.11.003↗
  28. A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT. First author DOI 10.18632/oncotarget.10776↗

Closest collaborators

The 25 strongest of 113 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Olivıer Turrini · 20 shared papers, 2016–2026 · strength 3.54
  2. Anaïs Palen · 5 shared papers, 2021–2026 · strength 1.33
  3. Christopher Lee Wolfgang · 5 shared papers, 2024–2026 · strength 1.21
  4. Alessio Marchetti · 5 shared papers, 2025–2026 · strength 1.15
  5. Greg D. Sacks · 5 shared papers, 2024–2026 · strength 1.11
  6. Ugo Marchèse · 9 shared papers, 2019–2025 · strength 1.06
  7. Ammar A. Javed · 5 shared papers, 2024–2026 · strength 1.03
  8. Jean‐Robert Delpéro · 10 shared papers, 2016–2021 · strength 0.99
  9. Marine Gilabert · 9 shared papers, 2016–2023 · strength 0.90
  10. Brice Chanez · 4 shared papers, 2023–2026 · strength 0.87
  11. Camila Hidalgo Salinas · 4 shared papers, 2025–2026 · strength 0.86
  12. Joseph R. Habib · 4 shared papers, 2024–2026 · strength 0.80
  13. Nelson Dusetti · 5 shared papers, 2016–2026 · strength 0.78
  14. Nicolas Alejandro Fraunhoffer · 3 shared papers, 2026 · strength 0.69
  15. Paul C. M. Andel · 3 shared papers, 2025–2026 · strength 0.63
  16. Daniel Brock Hewitt · 3 shared papers, 2024–2025 · strength 0.59
  17. Marc G. Besselink · 2 shared papers, 2026 · strength 0.54
  18. Roberto Salvia · 3 shared papers, 2021–2026 · strength 0.52
  19. Giampaolo Perri · 2 shared papers, 2026 · strength 0.52
  20. Michael D. Kluger · 2 shared papers, 2026 · strength 0.52
  21. Juan Iovanna · 4 shared papers, 2016–2026 · strength 0.51
  22. Marc F. Giovannini · 6 shared papers, 2016–2020 · strength 0.51
  23. Christophe Laurent · 3 shared papers, 2021–2025 · strength 0.46
  24. Oscar Mazza · 2 shared papers, 2026 · strength 0.42
  25. María Eugenia Pasqualini · 2 shared papers, 2026 · strength 0.42

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.